1. Broadening Eligibility Criteria for Oncology Clinical Trials: Current Advances and Future Directions. Issue 3 (8th July 2020) Authors: Rahman, Nam Atiqur; Ison, Gwynn; Beaver, Julia A. Journal: Clinical pharmacology & therapeutics Issue: Volume 108:Issue 3(2020) Page Start: 419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Issue 30 (20th October 2022) Authors: Fourie Zirkelbach, Jeanne; Shah, Mirat; Vallejo, Jonathon; Cheng, Joyce; Ayyoub, Amal; Liu, Jiang; Hudson, Rachel; Sridhara, Rajeshwari; Ison, Gwynn; Amiri-Kordestani, Laleh; Tang, Shenghui; Gwise, Thomas; Rahman, Atiqur; Pazdur, Richard; Theoret, Marc R. Journal: Journal of clinical oncology Issue: Volume 40:Issue 30(2022) Page Start: 3489 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. Issue 11 (November 2021) Authors: Gao, Jennifer J; Cheng, Joyce; Prowell, Tatiana M; Bloomquist, Erik; Tang, Shenghui; Wedam, Suparna B; Royce, Melanie; Krol, Danielle; Osgood, Christy; Ison, Gwynn; Sridhara, Rajeshwari; Pazdur, Richard; Beaver, Julia A; Amiri-Kordestani, Laleh Journal: Lancet oncology Issue: Volume 22:Issue 11(2021) Page Start: 1573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗